Two companies announced on Thursday that rare disease drugmaker Catalyst Pharmaceuticals will be acquired by healthcare group Angelini Pharma for $4.1 billion.

Angelini offered $31.50 per share, representing a total consideration of approximately €3.5 billion, equivalent to $4.1 billion. The acquisition price represents a 21% premium over the stock's closing price on April 22, the last unaffected trading day prior to the leak of merger news.

The President and CEO of Catalyst stated that this transaction provides shareholders with certain cash returns and a significant premium.

Angelini plans to integrate Catalyst's drug pipeline and commercial channels with its own expertise and products in the brain health field to build a next-generation rare disease treatment platform.

The merger is expected to create a scalable rare disease business platform, expanding global drug accessibility. The boards of both companies have unanimously approved the transaction, which is anticipated to close in the third quarter of 2026.

This acquisition also marks Angelini's official entry into the US market. Angelini is part of the Angelini Industries Group, with businesses spanning consumer goods, industrial technology, and healthcare.

The transaction involved participation from Blackstone funds, with financing support provided by BNP Paribas.